

**For more information, contact:**

Ed Field, President and COO  
Aldagen  
919-484-2571  
[efield@aldagen.com](mailto:efield@aldagen.com)

Michelle Linn  
Linnden Communications  
508-362-3087  
[linnmich@comcast.net](mailto:linnmich@comcast.net)

**FOR IMMEDIATE RELEASE****Aldagen, Inc. Appoints William E. Evans, PharmD to Board of Directors**

- Dr. Evans is Director and Chief Executive Officer of St. Jude Children's Research Hospital -

**Durham, NC – July 22, 2008** – Aldagen, Inc. today announced the appointment of William E. Evans, PharmD to its Board of Directors. Dr. Evans has been with St. Jude Children's Research Hospital since 1973, and began serving as director and chief executive officer in 2004. Dr. Evans' research at St. Jude Children's Research Hospital has focused on pediatric diseases and disorders, and he has authored more than 300 articles and book chapters. Dr. Evans has received several national awards for his research, including three consecutive National Institutes of Health MERIT Awards from the National Cancer Institute.

"We are very pleased to welcome Bill to our board of directors," said Tom Amick, Chairman and Chief Executive Officer of Aldagen. "Bill brings a unique combination of business acumen from running a 3,000 employee organization with a distinguished research career."

Dr. Evans is a licensed pharmacist and holds a Doctor of Pharmacy degree from the College of Pharmacy, University of Tennessee. He is a member of the Graduate Faculty and Professor of Pharmacy and Pharmaceutics in the College of Pharmacy, as well as a Professor of Pediatrics in the College of Medicine, at the University of Tennessee, Memphis. Dr. Evans is also a member of the Institute of Medicine of the National Academy of Sciences.

**About Aldagen, Inc.**

Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. The company has four product candidates in clinical trials. Aldagen's most advanced product candidate, ALD-101, is currently in a pivotal Phase 3 clinical trial to evaluate its efficacy in improving umbilical cord blood transplants used to treat inherited metabolic diseases in pediatric patients. The company also is conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates: ALD 151 to improve umbilical cord blood transplants used in the treatment of leukemia, ALD-301 to treat critical limb ischemia, and ALD-201 to treat ischemic heart failure. Aldagen's product candidates consist of specific populations of adult stem cells that the company isolates using its proprietary technology.

###